Worth reading
53Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Results for this period
Full year2022年4月1日〜2023年3月31日ConsolidatedIFRSNet Sales144,175million yenYear on year +4.9%Progress 99.4%
Operating profit30,049million yenYear on year -8.8%Progress 93.9%
Ordinary income30,489million yenYear on year -8.4%Progress 93.8%
Net income attributable to owners of the parent22,812million yenYear on year -8.7%Progress 91.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share338.70円
Operating Margin20.8%
Financial position at period-end
Total assets237,451million yen
of which net assets 195,933 million yenEquity ratio 82.4%vs. prior year-end +0.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+26,170
Investment-17,631
Financials-9,605
Net change-1,066
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period60,047 million yen
Segment revenuePharmaceuticals Business 121,988 million yen (YoY +1.1%), Functional Foods Business 22,187 million yen (YoY +31.8%)
Segment profitPharmaceuticals Business 28,771 million yen, Functional Foods Business 574 million yen
Regional sales95,029 million yen, 37,925 million yen, 37,628 million yen, 11,220 million yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales145,000 million yen (YoY +0.5%)
Operating profit32,000 million yen (YoY +6.5%)
Ordinary income32,500 million yen (YoY +6.6%)
Net income25,000 million yen (YoY +9.6%)
Annual Dividend Forecast¥114 per share → ¥120 per share
Payout ratioCurrent fiscal year 33.7% / Next-year forecast 32.3%
Shareholder Return Policy第六次中期経営計画期間中（2019年4月〜2024年3月）は連結配当性向35％前後の配当を行う方針
Factors Behind Changes in Business Performance
ウプトラビ、同製品の海外売上に伴うロイヤリティ収入、ビルテプソなどが伸長し売上収益が増加。前期にあった優先審査バウチャーの売却一時金収入の反動などにより利益は減少。
Disclosure regarding the going concern assumption
Not applicable (no matters to report in the notes on the going concern assumption)
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidation新規0社、除外0社（社名はいずれも記載なし）
Material subsequent eventsNo applicable matters.
Depreciation and amortization5,041 million yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and securities analysts)
Issued Shares at Period-End70,251,484
Treasury Shares at Period-End2,898,610
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2022年4月1日〜2023年3月31日 |
| Net Sales | 144,175 million yen (YoY +4.9%) |
| Operating profit | 30,049 million yen (YoY -8.8%) |
| Ordinary income | 30,489 million yen (YoY -8.4%) |
| Profit attributable to owners of the parent | 22,812 million yen (YoY -8.7%) |
| Net income per share | 338.70円 |
| Operating Margin | 20.8% |
| Equity ratio | End of the current fiscal period 82.4% / End of previous period 82.1% |
| Total assets | 237,451 million yen |
| Net assets | 195,933 million yen |
| Cash flows from operating activities | 26,170 million yen |
| Cash flows from investing activities | -17,631 million yen |
| Cash flows from financing activities | -9,605 million yen |
| Cash and cash equivalents at end of period | 60,047 million yen |
| Full-year earnings forecast | Net Sales 145,000 million yen (YoY +0.5%) / Operating profit 32,000 million yen (YoY +6.5%) / Ordinary income 32,500 million yen (YoY +6.6%) / Net income 25,000 million yen (YoY +9.6%) |
| Annual Dividend Forecast | ¥114 per share → ¥120 per share |
| Payout ratio | Current fiscal year 33.7% / Next-year forecast 32.3% |
| Shareholder Return Policy | 第六次中期経営計画期間中（2019年4月〜2024年3月）は連結配当性向35％前後の配当を行う方針 |
| Segment revenue | Pharmaceuticals Business 121,988 million yen (YoY +1.1%), Functional Foods Business 22,187 million yen (YoY +31.8%) |
| Segment profit | Pharmaceuticals Business 28,771 million yen, Functional Foods Business 574 million yen |
| Regional sales | 95,029 million yen, 37,925 million yen, 37,628 million yen, 11,220 million yen |
| Depreciation and amortization | 5,041 million yen |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | 新規0社、除外0社（社名はいずれも記載なし） |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 70,251,484 |
| Treasury Shares at Period-End | 2,898,610 |
| Factors Behind Changes in Business Performance | ウプトラビ、同製品の海外売上に伴うロイヤリティ収入、ビルテプソなどが伸長し売上収益が増加。前期にあった優先審査バウチャーの売却一時金収入の反動などにより利益は減少。 |
Items this document does not state (4)
Revision to Earnings ForecastOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ウプトラビ、同製品の海外売上に伴うロイヤリティ収入、ビルテプソなどが伸長した。利益面では、前期にあった優先審査バウチャーの売却一時金収入の反動などにより減益となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.